

? S PN=DE 19834591
85 1 PN=DE 19834591
? T 5/3,AB/1

5/3,AB/1

DIALOG(R) File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

012990264

WPI Acc No: 2000-162116/*200015*

XRAM Acc No: C00-050845

Use of substances that decrease the activity of dipeptidyl peptidase IV
to increase blood sugar levels, e.g. for treating hypoglycemia
Patent Assignee: PROBIODRUG GES ARZNEIMITTELFORSCUNG MBH (PROB-N); DEMUTH
H (DEMUTH-I); HOFFMANN T (HOFF-I); KUHN-WACHE K (KUHN-I); ROSCHE F (ROSC-I)
; PROBIODRUG (PROB-N)

Inventor: DEMUTH H; HOFFMANN T; KUEHN-WACHE K; ROSCHE F; KUHN-WACHE K

Number of Countries: 026 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
DE 19834591	A1	20000203	DE 1034591	A	19980731	200015 B
EP 995440	A1	20000426	EP 99115236	A	19990802	200025
US 6319893	B1	20011120	US 99365404	A	19990802	200174
US 20020071838	A1	20020613	US 99365404	A	19990802	200243
			US 2001682968	A	20011102	

Priority Applications (No Type Date): DE 1034591 A 19980731

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

DE 19834591	A1	7		A61K-038/55	
-------------	----	---	--	-------------	--

EP 995440	A1	G		A61K-031/425	
-----------	----	---	--	--------------	--

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT
LI LT LU LV MC MK NL PT RO SE SI

US 6319893	B1			A01N-037/18	
------------	----	--	--	-------------	--

US 20020071838	A1			A61K-038/47	Div ex application US 99365404
----------------	----	--	--	-------------	--------------------------------

Abstract (Basic): *DE 19834591* A1

Abstract (Basic):

NOVELTY - The use of substances (I) that decrease the activity of dipeptidyl peptidase IV (DP IV) to increase blood sugar levels above the glucose concentration characteristic of hypoglycemia in the serum of mammals.

ACTIVITY - Antidiabetic.

MECHANISM OF ACTION - Inhibitor of glucagon degradation by DP IV.

USE - (I) are useful for increasing blood sugar levels by inhibiting the degradation of glucagon (endogenous or administered) by DP IV (dipeptidyl peptidase IV) and can therefore be used for treating metabolic disorders caused by subnormal glucose levels, especially hypoglycemia associated with diabetes.

ADVANTAGE - Only small amounts of (I) are required to protect glucagon from rapid proteolytic degradation by DP IV.

pp; 7 DwgNo 0/4